Parkinson’s Disease Therapeutics Market (By Drug Class: Levodopa/Carbidopa, Dopamine Agonists, Adenosine A2A Antagonist, COMT Inhibitors, MAO-B Inhibitors, Glutamate Antagonist, Others; By Route of Administration: Oral, Subcutaneous, Transdermal, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Parkinson’s Disease Therapeutics Market 

5.1. COVID-19 Landscape: Parkinson’s Disease Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Parkinson’s Disease Therapeutics Market, By Drug Class

8.1. Parkinson’s Disease Therapeutics Market, by Drug Class, 2024-2033

8.1.1 Levodopa/Carbidopa

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Dopamine Agonists

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Adenosine A2A Antagonist

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. COMT Inhibitors

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. MAO-B Inhibitors

8.1.5.1. Market Revenue and Forecast (2021-2033)

8.1.6. Glutamate Antagonist

8.1.6.1. Market Revenue and Forecast (2021-2033)

8.1.7. Others

8.1.7.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Parkinson’s Disease Therapeutics Market, By Route of Administration

9.1. Parkinson’s Disease Therapeutics Market, by Route of Administration, 2024-2033

9.1.1. Oral

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Subcutaneous

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Transdermal

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Parkinson’s Disease Therapeutics Market, By Patient 

10.1. Parkinson’s Disease Therapeutics Market, by Patient, 2024-2033

10.1.1. Adult

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Pediatric

10.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Parkinson’s Disease Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.1.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.1.3. Market Revenue and Forecast, by Patient (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.1.4.3. Market Revenue and Forecast, by Patient (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.1.5.3. Market Revenue and Forecast, by Patient (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.2.3. Market Revenue and Forecast, by Patient (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.2.4.3. Market Revenue and Forecast, by Patient (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.2.5.3. Market Revenue and Forecast, by Patient (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.2.6.3. Market Revenue and Forecast, by Patient (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.2.7.3. Market Revenue and Forecast, by Patient (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.3.3. Market Revenue and Forecast, by Patient (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.3.4.3. Market Revenue and Forecast, by Patient (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.3.5.3. Market Revenue and Forecast, by Patient (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.3.6.3. Market Revenue and Forecast, by Patient (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.3.7.3. Market Revenue and Forecast, by Patient (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.4.3. Market Revenue and Forecast, by Patient (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.4.4.3. Market Revenue and Forecast, by Patient (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.4.5.3. Market Revenue and Forecast, by Patient (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.4.6.3. Market Revenue and Forecast, by Patient (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.4.7.3. Market Revenue and Forecast, by Patient (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.5.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.5.3. Market Revenue and Forecast, by Patient (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.5.4.3. Market Revenue and Forecast, by Patient (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Route of Administration (2021-2033)

11.5.5.3. Market Revenue and Forecast, by Patient (2021-2033)

Chapter 12. Company Profiles

12.1. Cerevel Therapeutics

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Hallamshire Physiotherapy Ltd

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Novartis AG

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Olatec Therapeutics

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Biotech Ltd

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Teva Pharmaceutical Industries Ltd.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Merck & Co., Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. GlaxoSmithKline plc. (GSK)

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. AbbVie, Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Acorda Therapeutics, Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample